4-(1,2,3-triazol-4-yl)benzoic acid | 1256164-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1,2,3-triazol-4-yl)benzoic acid
• 英文别名: 4-(1H-1,2,3-triazol-4-yl)benzoic acid；4-(2H-triazol-4-yl)benzoic acid
• CAS: 1256164-21-2
• 化学式: C₉H₇N₃O₂
• 分子量: 189.173
• InChiKey: QMHVMBUQARDKEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  zinc(II) nitrate hexahydrate 、 4-(1,2,3-triazol-4-yl)benzoic acid 、 N,N-二甲基甲酰胺 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  基于双功能配体和五核锌簇团的多孔双壁金属三唑盐骨架，选择性吸收CO 2。

  摘要：

  定制设计的具有1,2,3-三唑酸酯和羧酸酯供体基团的双功能配体与原位生成的五核锌簇的自组装提供了双壁金属三唑酸酯骨架（MTAF）材料MTAF-1（Zn 5（μ 3 -O）2（C 9 ñ 3 ħ 5 ö 2）5（H +）4（H 2 O）17（C 3 H ^ 7 NO）10），其表现出2300 m的表面区域2 / g并证明有趣的选择性CO 2吸收性能。

  DOI：

  10.1021/ic3002256
• 作为产物：
  描述：

  C₂₇H₂₅N₄O₅Pol 在 水 、 三氟乙酸 作用下， 反应 24.0h， 生成 4-(1,2,3-triazol-4-yl)benzoic acid
  参考文献：
  名称：

  通过铜催化的叠氮化物-炔烃环加成反应固相合成N H-1,2,3-三唑的无痕叠氮基接头

  摘要：

  对的固相合成中的广泛有用酸不稳定无痕叠氮基连接基Ñ H-1,2,3-三唑被呈现。各种炔烃通过Cu（I）介导的叠氮化物-炔烃环加成反应有效地固定在一系列聚合物载体上。负载的三唑显示出与后续肽化学的优异相容性。通过用TFA水溶液处理，很容易从固体载体中释放出纯物质（通常> 95％）。

  DOI：

  10.1021/ol102209p

文献信息

• Metal polishing slurry
  申请人：FUJIFILM Corporation

  公开号：EP1837903A2

  公开（公告）日：2007-09-26

  The metal polishing slurry according to the present invention for use in chemical mechanical polishing during semiconductor device fabrication contains at least one compound of formula (A) below and at least one compound of formula (B) or formula (C) below: [wherein R1, R2, R3, R4 and R5 are each independently hydrogen, methyl, ethyl, phenyl, amino, sulfo, carboxy, aminomethyl, carboxymethyl, sulfomethyl, o-aminophenyl, m-aminophenyl, p-aminophenyl, o-carboxyphenyl, m-carboxyphenyl, p-carboxyphenyl, o-sulfophenyl, m-sulfophenyl or p-sulfophenyl].

  根据本发明，在半导体器件制造过程中用于化学机械抛光的金属抛光浆料含有至少一种下式（A）化合物和至少一种下式（B）或（C）化合物： [其中 R1、R2、R3、R4 和 R5 各自独立地为氢、甲基、乙基、苯基、氨基、磺基、羧基、氨基甲基、羧基甲基、磺基甲基、邻氨基苯基、间氨基苯基、对氨基苯基、邻羧基苯基、间羧基苯基、对羧基苯基、邻磺基苯基、间磺基苯基或对磺基苯基]。
• Compounds and their use for reducing uric acid levels
  申请人：Acquist LLC

  公开号：US10759784B2

  公开（公告）日：2020-09-01

  Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders of uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.

  提供了可增加尿酸排泄和减少尿酸生成的双官能化合物，以及可增加尿酸排泄或减少尿酸生成的单官能化合物。还提供了使用这些化合物降低血液或血清中尿酸水平、治疗尿酸代谢紊乱以及维持血液或血清中正常尿酸水平的方法。还提供了包含双官能和单官能化合物的药物组合物。
• COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
  申请人：Minutolo Filippo

  公开号：US20120309794A1

  公开（公告）日：2012-12-06

  The present invention concerns compounds, some of which are novel, and their pharmaceutical applications. The compounds of the invention inhibit the enzyme lactate dehydrogenase (LDH) involved both in the metabolic process of hypoxic tumour cells, and in the process used by parasitic protozoa that cause malaria to obtain most of the energy they need.
• METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE
  申请人：THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

  公开号：US20200239512A1

  公开（公告）日：2020-07-30

  The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.
• Compounds and Their Use for Reducing Uric Acid Levels
  申请人：Acquist LLC

  公开号：US20200347034A1

  公开（公告）日：2020-11-05

  Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders of uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.